Companies · Biotechnology

BIO-NEMS Corp

MENLO PARK · Biotechnology

Diligence memoA one-page analyst read on BIO-NEMS Corp — recommendation, valuation, rhythm, risks.
$1.5M
Total raised · real
4
Rounds
0.4×
Latest step-up
Top 77%
Sector rank · raised
Pre-Seed
Latest stage · inferred · Mon Dec 19 2016 00:00:00 GMT+0000 (Coordinated Universal Time)

BIO-NEMS Corp looks under-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.47× the median modeled value of Pre-Seed Biotechnology companies in 2016–2018 (152 peers) — value vs value, same stage and era.
Dormant
  • Last raise 9.5 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

BIO-NEMS Corp is one of 4291 Biotechnology companies tracked from MENLO PARK. By capital raised it ranks in the long tail (ahead of 24% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
22
Investors (latest)
2011
Year incorporated
2016-12-19
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$13M$25M$38M$50MPre-Seed · 2012-11-05 Raised $725K (real) Modeled valuation $40M (est)$725K$40MPre-Seed2012Pre-Seed · 2013-12-05 Raised $200K (real) Modeled valuation $11M (est)$200K$11MPre-Seed2013Pre-Seed · 2013-12-05 Raised $100K (real) Modeled valuation $5.5M (est)$100K$5.5MPre-Seed2013Pre-Seed · 2015-10-19 Raised $414K (real) Modeled valuation $23M (est)$414K$23MPre-Seed2015Pre-Seed · 2016-12-19 Raised $182K (real) Modeled valuation $10M (est)$182K$10MPre-Seed2016+$200K+$100K+$414K+$182KCumulative $1.6M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$725K · 2012
Pre-Seed extension$200K · 2013
Pre-Seed extension$100K · 2013
Pre-Seed extension$414K · 2015
Pre-Seed extension$182K · 2016

Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.

Modeled valuation trajectory
$10.0M
Base estimate est.
$97K
Conservative case
$113.7M
Upside case
$1.0M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Pre-Seeda round under $1.0M). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Pre-Seed · modeled $40.0M · 2012-11-052012Pre-Seed · modeled $11.0M · 2013-12-05Pre-Seed · modeled $5.5M · 2013-12-05Pre-Seed · modeled $22.9M · 2015-10-19Pre-Seed · modeled $10.0M · 2016-12-192016
Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
24%
Survival probability
10% low · 44% high
1.86×/yr
Annual markup
2.52×/yr upside case
6.0 yr
Elapsed time used
9.5 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
12 mo
Avg between rounds
$369K/yr
Capital velocity
13.7 yr
On record since
2012
First round
5
Rounds on file
How it compares to the market

Benchmarked against 4291 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 0.2× of median
This company$1.5M
Sector median$7.2M
Latest round — vs other Pre-Seed rounds in sector (real $, this stage) 0.4× of median
This company$182K
Sector median$412K
Modeled value — vs sector median (estimate, all stages) 0.2× of median
This company$10.0M
Sector median$64.2M

Raised more than 24% of sector peers (real $). Modeled value above 19% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Pre-Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #121 of 152.

This companyCohort peer
$1.0M$10.0M$100.0M$100K$1.0M$10.0MCapital raised (log)Cerebral Magnetics INC · Pre-Seed Raised $1.0M · modeled $55.2M (est)AnTolRx, Inc. · Pre-Seed Raised $1.0M · modeled $55.2M (est)NutriBand Inc. · Pre-Seed Raised $1.2M · modeled $55.2M (est)US Biologic, Inc. · Pre-Seed Raised $1.0M · modeled $55.2M (est)New Vital Signs, Inc. · Pre-Seed Raised $1.0M · modeled $55.2M (est)Jivana Biotechnology Inc · Pre-Seed Raised $2.0M · modeled $55.2M (est)Zeta Biolongevity, Inc. · Pre-Seed Raised $995K · modeled $54.9M (est)ALRGN Bio, Inc. · Pre-Seed Raised $946K · modeled $52.2M (est)BioSurfaces, LLC · Pre-Seed Raised $900K · modeled $49.7M (est)Cellsolutions Llc · Pre-Seed Raised $1.9M · modeled $49.7M (est)Pique Therapeutics, Inc. · Pre-Seed Raised $1.4M · modeled $47.2M (est)NeuExCell Therapeutics Inc. · Pre-Seed Raised $850K · modeled $46.9M (est)BIO-NEMS Corp (this company) Raised $1.5M · modeled $10.0M (est)BIO-NEMS Corp
CompanyStageRaised · realValue · estvs peer med.
Cerebral Magnetics INCPre-Seed$1.0M$55.2M2.61×
AnTolRx, Inc.Pre-Seed$1.0M$55.2M2.61×
NutriBand Inc.Pre-Seed$1.2M$55.2M2.61×
US Biologic, Inc.Pre-Seed$1.0M$55.2M2.61×
New Vital Signs, Inc.Pre-Seed$1.0M$55.2M2.61×
Jivana Biotechnology IncPre-Seed$2.0M$55.2M2.61×
Zeta Biolongevity, Inc.Pre-Seed$995K$54.9M2.60×
ALRGN Bio, Inc.Pre-Seed$946K$52.2M2.47×
BioSurfaces, LLCPre-Seed$900K$49.7M2.35×
Cellsolutions LlcPre-Seed$1.9M$49.7M2.35×
Pique Therapeutics, Inc.Pre-Seed$1.4M$47.2M2.23×
NeuExCell Therapeutics Inc.Pre-Seed$850K$46.9M2.22×
BIO-NEMS Corp this companyPre-Seed$1.5M$10.0M0.47×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$725K2012-11-05$4.0M$40.0M85%
Pre-Seed$200K2013-12-05$1.1M$11.0M85%
Pre-Seed$100K2013-12-05$556K$5.5M85%
Pre-Seed$414K2015-10-19$2.3M$22.9M85%
Pre-Seed$182K2016-12-19$1.0M$10.0M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$725K2012-11-05
    • First recorded raise — entered as Pre-Seed.
    • 4 investors on this round.
  2. Pre-Seed$200K2013-12-05
    • Raised 13 mo later, in step with the ~14 mo sector norm.
    • Round 3.6× smaller than the prior — bridge or down round.
    • Switched to Rule 506(b) (was Rule 06).
    • 1 investor on this round.
  3. Pre-Seed$100K2013-12-05
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 2.0× smaller than the prior — bridge or down round.
    • 1 investor on this round.
  4. Pre-Seed$414K2015-10-19
    • Raised again after 22 mo — slower than the ~14 mo sector norm.
    • Round 4.1× larger than the prior — scaling up.
    • 15 investors on this round.
  5. Pre-Seed$182K2016-12-19
    • Raised 14 mo later, in step with the ~14 mo sector norm.
    • Round 2.3× smaller than the prior — bridge or down round.
    • 22 investors on this round.
Intelligence
2017 ~Q4
Modeled next raise · ~12mo cadence
$182K
Modeled next size est.range $182K$291K
0.4×
Last step-up
$369K/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Paul Russo3 other2016-12
Leslie L. Vadasz2 other2013-12
Regis McKenna2 other2016-12
Paul L. Russo1 other2015-10
David Medin2012-11
Jaleh Daie2016-12
Jim Russ Moniz2012-11
Regis L. McKenna2015-10
S Russ Lehrman2012-11
Registry & provenance

BIO-NEMS Corp is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1562529
SEC CIK
2011
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
OrthoFundamentals, LLCBiotechnologyPre-Seed$1.5M$7.0Msame sector · same stage
AvanSci Bio, L.L.C.BiotechnologyPre-Seed$1.5M$8.8Msame sector · same stage
Arrevus, Inc.BiotechnologyPre-Seed$1.4M$8.3Msame sector · same stage
PolyPlexx, LLCBiotechnologyPre-Seed$1.4M$11.4Msame sector · same stage
Avenzoar Pharmaceuticals, Inc.BiotechnologyPre-Seed$1.4M$8.1Msame sector · same stage
Sarcio, Inc.BiotechnologyPre-Seed$1.4M$13.4Msame sector · same stage
Cypris Medical, Inc.BiotechnologyPre-Seed$1.7M$8.3Msame sector · same stage
Endonovo Therapeutics, Inc.BiotechnologyPre-Seed$1.7M$12.4Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Nexsis Biosciences LLCBiotechnologyPre-Seed$16.0M90%
NE1 Inc.BiotechnologySeed$29.2M88%
NERx Biosciences, Inc.BiotechnologyPre-Seed$4.8M87%
Neuros Medical, Inc.BiotechnologySeries C$338.1M87%
NemaMetrix Inc.BiotechnologySeries A$186.6M87%
Nexeon Medsystems IncBiotechnologySeries B$46.2M87%
NGM Bio Holdings, Inc.BiotechnologySeries C$649.8M86%
ARTMS Inc.BiotechnologySeries A$174.7M86%
Frequently asked
How much funding has BIO-NEMS Corp raised?
BIO-NEMS Corp has raised approximately $1.5M in disclosed capital across 4 recorded financing rounds, aggregated from public filings.
What is BIO-NEMS Corp's estimated valuation?
Provath's modeled valuation for BIO-NEMS Corp is approximately $10.0M (modeled range $97K–$113.7M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is BIO-NEMS Corp at?
BIO-NEMS Corp's latest modeled financing stage is Pre-Seed. Its most recent recorded round closed around Mon Dec 19.
What does BIO-NEMS Corp do and where is it based?
BIO-NEMS Corp operates in the Biotechnology sector, based in MENLO PARK.
Explore related

See where BIO-NEMS Corp sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at BIO-NEMS Corp, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.